FDA Issues Ultimatum Following Year-Long Addyi Controversy
The U.S. Food and Drug Administration (FDA) has a reputation as an organization firmly devoted to the safety and protection of consumers from the ravishes of unsafe and unchecked pharmaceuticals and other products entering the consumer market. Although they take this duty very seriously, they must also make allowances for new … [Read more...]
Harmful Diseases Linked to Defective Drug or Toxic Substance
Harmful Diseases Linked To Drugs And Hazardous Chemicals. Many people with a particular disease or disorder may not realize it through the haze of symptoms from which they are suffering, but their illness could possibly be connected to a defective drug they have been taking, or are still taking. Also, exposure to hazardous chemicals … [Read more...]
National Defective Drug Attorneys Warn That Newly Approved Generic Actos Has Similar Risk Of Bladder Cancer, Other Side Effects
Generic Actos Has Similar Risk Of Bladder Cancer. Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is warning consumers that generic versions of Actos, like the brand name, carry an increased risk of bladder cancer and other complications. The U.S. Food and Drug … [Read more...]
Defective Drug Lawyers File Lawsuit on Actos
Defective Drug Lawyers File Lawsuit On Behalf Of Patient Who Took Actos. Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Kentucky woman naming Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda … [Read more...]
Avastin Study Finds Increased Death Risk
Cancer patients treated with Avastin are 50 percent more likely to die than those treated with chemotherapy alone, according to a new study. The same study found that when patients are treated with Avastin and certain chemotherapy drugs - taxanes or platinum medications - risks for fatal Avastin side effects like bleeding, blood … [Read more...]
NEJM Sides With Plaintiff In Defective Drug Lawsuit Preemption Case
NEJM Sides With Plaintiff In Defective Drug Lawsuit. The New England Journal of Medicine (NEJM) has come down on the side of consumers in a vital Supreme Court case that could have far reaching effects on the rights of patients to sue over injuries cased by defective drugs. According to the editors of the NEJM, if the Court sides … [Read more...]
Digitek Lawsuit Claims Permanent Heart Damage
Digitek Lawsuit Claims Defective Drug. In the first federal suit filed over Digitek, Bobbie Dyal and Robert Dyal, from Talladega, Alabama are suing Actavis Totowa the maker of a heart drug Digitek, which was used to treat heart failure and abnormal heart rhythms. In April 2008, Actavis recalled all lots of Bertek and UDL … [Read more...]
FDA Deadlines Responsible for Defective Drug Approvals
Defective Drug Approvals. Defective drugs are more likely to be approved by the Food & Drug Administration (FDA) because of tight time constraints the agency must work under, new research has found. A new study by Harvard researchers who have analyzed decades of drug approvals has revealed that those drugs that are approved … [Read more...]
Vioxx Grand Jury Probe Headache for Merck
Vioxx Grand Jury Probe. Just as Vioxx maker Merck gets closer to settling thousands of lawsuits against the defective pain reliever, reports have surfaced that a grand jury is investigating the company over the way it marketed Vioxx. According to the Wall Street Journal, the health-care-fraud unit of the U.S. Attorney's Office … [Read more...]
Ketek Investigation Could Yield Subpoenas
Ketek Investigation Yield Subpoenas. Ketek investigators at the Food & Drug Administration (FDA) could soon be subpoenaed by a congressional committee looking into the agency’s handling of the defective drug. Ketek, approved in 2004 to treat respiratory tract infections, bronchitis, sinusitis and community-acquired pneumonia, … [Read more...]
Big Vioxx Settlement Deadline Today
Big Vioxx Settlement. Vioxx patients who where injured by the defective drug have until the end of business today to decide whether or not to take part in a proposed $4.85 billion settlement with Merck Inc. According to Bloomberg.com, about half of the 60,800 people who sued have already signed up. Of those, 29,000 claimed heart … [Read more...]
